Canada · Delayed Price · Currency is CAD BioSyent Statistics
Total Valuation
BioSyent has a market cap or net worth of CAD 200.17 million. The enterprise value is 194.36 million.
| Market Cap | 200.17M |
| Enterprise Value | 194.36M |
Important Dates
The next estimated earnings date is Tuesday, November 17, 2026.
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | Aug 31, 2026 |
Share Statistics
BioSyent has 11.31 million shares outstanding. The number of shares has decreased by -0.72% in one year.
| Current Share Class | 11.31M |
| Shares Outstanding | 11.31M |
| Shares Change (YoY) | -0.72% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 9.56% |
| Owned by Institutions (%) | 10.19% |
| Float | 9.14M |
Valuation Ratios
The trailing PE ratio is 20.72 and the forward PE ratio is 17.10.
| PE Ratio | 20.72 |
| Forward PE | 17.10 |
| PS Ratio | 3.60 |
| PB Ratio | 4.37 |
| P/TBV Ratio | 10.29 |
| P/FCF Ratio | 17.47 |
| P/OCF Ratio | 17.40 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.88, with an EV/FCF ratio of 16.96.
| EV / Earnings | 19.70 |
| EV / Sales | 3.49 |
| EV / EBITDA | 12.88 |
| EV / EBIT | 14.70 |
| EV / FCF | 16.96 |
Financial Position
The company has a current ratio of 2.07, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.07 |
| Quick Ratio | 1.13 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | 0.27 |
| Interest Coverage | 124.01 |
Financial Efficiency
Return on equity (ROE) is 23.65% and return on invested capital (ROIC) is 24.56%.
| Return on Equity (ROE) | 23.65% |
| Return on Assets (ROA) | 15.90% |
| Return on Invested Capital (ROIC) | 24.56% |
| Return on Capital Employed (ROCE) | 28.33% |
| Weighted Average Cost of Capital (WACC) | 8.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 1.07 |
| Inventory Turnover | 1.90 |
Taxes
In the past 12 months, BioSyent has paid 3.51 million in taxes.
| Income Tax | 3.51M |
| Effective Tax Rate | 26.26% |
Stock Price Statistics
The stock price has increased by +63.89% in the last 52 weeks. The beta is 0.70, so BioSyent's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +63.89% |
| 50-Day Moving Average | 16.47 |
| 200-Day Moving Average | 15.00 |
| Relative Strength Index (RSI) | 64.46 |
| Average Volume (20 Days) | 8,588 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSyent had revenue of CAD 55.67 million and earned 9.87 million in profits. Earnings per share was 0.85.
| Revenue | 55.67M |
| Gross Profit | 40.85M |
| Operating Income | 13.22M |
| Pretax Income | 13.38M |
| Net Income | 9.87M |
| EBITDA | 14.88M |
| EBIT | 13.22M |
| Earnings Per Share (EPS) | 0.85 |
Balance Sheet
The company has 8.94 million in cash and 3.14 million in debt, with a net cash position of 5.80 million or 0.51 per share.
| Cash & Cash Equivalents | 8.94M |
| Total Debt | 3.14M |
| Net Cash | 5.80M |
| Net Cash Per Share | 0.51 |
| Equity (Book Value) | 45.84M |
| Book Value Per Share | 4.04 |
| Working Capital | 14.74M |
Cash Flow
In the last 12 months, operating cash flow was 11.50 million and capital expenditures -45,642, giving a free cash flow of 11.46 million.
| Operating Cash Flow | 11.50M |
| Capital Expenditures | -45,642 |
| Depreciation & Amortization | 1.66M |
| Net Borrowing | 1.67M |
| Free Cash Flow | 11.46M |
| FCF Per Share | 1.01 |
Margins
Gross margin is 73.38%, with operating and profit margins of 23.74% and 17.73%.
| Gross Margin | 73.38% |
| Operating Margin | 23.74% |
| Pretax Margin | 24.04% |
| Profit Margin | 17.73% |
| EBITDA Margin | 26.73% |
| EBIT Margin | 23.74% |
| FCF Margin | 20.58% |
Dividends & Yields
This stock pays an annual dividend of 0.22, which amounts to a dividend yield of 1.24%.
| Dividend Per Share | 0.22 |
| Dividend Yield | 1.24% |
| Dividend Growth (YoY) | 10.26% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 24.01% |
| FCF Payout Ratio | 21.71% |
| Buyback Yield | 0.72% |
| Shareholder Yield | 1.97% |
| Earnings Yield | 4.83% |
| FCF Yield | 5.72% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioSyent has an Altman Z-Score of 8.79 and a Piotroski F-Score of 5.
| Altman Z-Score | 8.79 |
| Piotroski F-Score | 5 |